Journey Medical Corporation faces a challenging path to profitability as its commercial infrastructure struggles to scale, evidenced by persistent negative operating margins that reached -77.4% in 2024Q1. While the company exhibits intermittent revenue growth,...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.01+55.6% vs -$0.02 | $19M+0.8% vs $18M |
Q2 2026 May 13, 2026 | -$0.08-14.3% vs -$0.07 | $16M+3.2% vs $15M |
Q2 2026 Mar 25, 2026 | -$0.04+33.3% vs -$0.06 | $16M-14.7% vs $19M |
Q4 2025 Nov 12, 2025 | -$0.09-12.5% vs -$0.08 | $18M-6.5% vs $19M |
Journey Medical (DERM) is rated Buy, driven by Emrosi's rapid prescription growth and expanding payer coverage. DERM leverages existing infrastructure for Emrosi, achieving high gross margins and operating leverage, pushing toward sustainable profitability. Conservative growth assumptions and a 4x EV/Sales multiple yield a $15 target price, implying 109% upside over three years.
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Journey Medical demonstrates strong Emrosi prescription growth, rebounding from Q1 lows with Q2 revenues up 23% to $18.5M and positive EBITDA. DERM's Emrosi franchise is gaining traction, with prescribers rising over 40% quarter-over-quarter and formulary coverage improving from 34% to 38%. Cost discipline is evident as SG&A declined and operating expenses rose less than 1%, while Emrosi's ASP and market penetration are expected to improve further.
Benchmark DERM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Journey Medical Corporation (DERM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.50 | $178.89M | -13.83 | 10.2% | -18.48% | -44.03% | — | |
| $0.68 | $87.7M | -4.23 | -10.02% | -9.79% | -47.84% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $136.49 | $9.45B | 39.22 | 30.73% | 12.29% | 26.69% | — | |
| $39.50 | $26.37M | -1.27 | 13.77% | -4417.28% | -199.65% | — |
Journey Medical Corporation (DERM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Journey Medical Corporation (DERM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jun 26, 2026·SEC
May 13, 2026·SEC
Get notified when DERM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Journey Medical Corporation (DERM) stock FAQ — growth, dividends, profitability & financials explained
Journey Medical Corporation (DERM) reported $68.2M in revenue for fiscal year 2025. This represents a 834% increase from $7.3M in 2014.
Journey Medical Corporation (DERM) grew revenue by 10.2% over the past year. This is steady growth.
Journey Medical Corporation (DERM) reported a net loss of $6.1M for fiscal year 2025.
Journey Medical Corporation (DERM) has a return on equity (ROE) of -44.0%. Negative ROE indicates the company is unprofitable.
Journey Medical Corporation (DERM) had negative free cash flow of $7.5M in fiscal year 2025, likely due to heavy capital investments.
